Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.65 | N/A | -98.78% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.65 | N/A | -98.78% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide specific forecasts.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
The earnings report indicates that 10X Genomics is facing significant challenges, as evidenced by the substantial EPS miss. The stock reacted negatively, dropping 3.85%, reflecting investor concerns about the company's performance and lack of guidance. Without clear revenue figures or future expectations, uncertainty remains high for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 9, 2020